LIGAND PHARMACEUTICALS INCORPORATED Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of $143.32 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2019-02-28
- LIGAND PHARMACEUTICALS INCORPORATED income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2017-12-31 was -$7.01M.
- LIGAND PHARMACEUTICALS INCORPORATED income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2017-09-30 was $8.43M, a 701.71% increase year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2017-06-30 was $6.06M.
- LIGAND PHARMACEUTICALS INCORPORATED income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2017-03-31 was $5.08M, a 13.58% decline year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2018 was $143.32M, a 1041.45% increase from fiscal 2017.
- LIGAND PHARMACEUTICALS INCORPORATED income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2017 was $12.56M.
- LIGAND PHARMACEUTICALS INCORPORATED income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2016 was -$2.37M, a 101.04% decline from fiscal 2015.
- LIGAND PHARMACEUTICALS INCORPORATED income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2015 was $227.44M, a 1988.17% increase from fiscal 2014.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2018-12-31 | $143.32M 10-K · filed 2019-02-28 | ||||||
| 2017-12-31 | -$7.01M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $1.42M derived: sum of 2 quarters · filed 2019-02-28 | $7.47M derived: sum of 3 quarters · filed 2019-02-28 | $12.56M 10-K · filed 2019-02-28 | |||
| 2017-09-30 | $8.43M 10-Q · filed 2017-11-09 | $14.48M derived: sum of 2 quarters · filed 2017-11-09 | $19.57M 10-Q · filed 2017-11-09 | $16.44M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2017-06-30 | $6.06M 10-Q · filed 2017-08-09 | $11.14M 10-Q · filed 2017-08-09 | $8.01M derived: sum of 3 quarters · filed 2019-02-28 | $9.06M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2017-03-31 | $5.08M 10-Q · filed 2017-05-09 | $1.95M derived: sum of 2 quarters · filed 2019-02-28 | $3.00M derived: sum of 3 quarters · filed 2019-02-28 | -$3.17M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2016-12-31 | -$3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | -$2.08M derived: sum of 2 quarters · filed 2019-02-28 | -$8.24M derived: sum of 3 quarters · filed 2019-02-28 | -$2.37M 10-K · filed 2019-02-28 | |||
| 2016-09-30 | $1.05M 10-Q · filed 2017-11-09 | -$5.12M derived: sum of 2 quarters · filed 2017-11-09 | $759.00K 10-Q · filed 2017-11-09 | $7.10M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2016-06-30 | -$6.17M 10-Q · filed 2017-08-09 | -$5.76M 10-Q · filed 2016-08-04 | -$293.00K 10-Q · filed 2017-08-09 | $114.00K 10-Q · filed 2016-08-04 | $6.05M derived: sum of 3 quarters · filed 2018-03-01 | $205.21M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-03-31 | $5.88M 10-Q · filed 2017-05-09 | $12.22M derived: sum of 2 quarters · filed 2018-03-01 | $211.38M derived: sum of 3 quarters · filed 2018-03-01 | $233.41M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2015-12-31 | $6.34M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $205.51M derived: sum of 2 quarters · filed 2018-03-01 | $227.53M derived: sum of 3 quarters · filed 2018-03-01 | $227.44M 10-K · filed 2018-03-01 | $254.93M 10-K · filed 2016-02-26 | ||
| 2015-09-30 | $199.16M 10-Q · filed 2016-11-14 | $221.19M derived: sum of 2 quarters · filed 2016-11-14 | $221.10M 10-Q · filed 2016-11-14 | $227.84M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-06-30 | $22.03M 10-Q · filed 2016-11-14 | $21.94M 10-Q · filed 2016-11-14 | $28.67M derived: sum of 3 quarters · filed 2017-02-28 | $29.45M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-03-31 | -$89.00K 10-Q · filed 2016-11-14 | $6.64M derived: sum of 2 quarters · filed 2017-02-28 | $7.42M derived: sum of 3 quarters · filed 2017-02-28 | $8.71M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2014-12-31 | $6.73M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $7.51M derived: sum of 2 quarters · filed 2017-02-28 | $8.80M derived: sum of 3 quarters · filed 2017-02-28 | $10.89M 10-K · filed 2017-02-28 | |||
| 2014-09-30 | $777.00K 10-Q · filed 2014-10-31 | $2.06M derived: sum of 2 quarters · filed 2014-10-31 | $4.16M 10-Q · filed 2014-10-31 | $6.03M derived: sum of 4 quarters · filed 2016-11-14 | |||
| 2014-06-30 | $1.29M 10-Q · filed 2014-08-05 | $3.38M 10-Q · filed 2014-08-05 | $5.25M derived: sum of 3 quarters · filed 2016-11-14 | $7.22M derived: sum of 4 quarters · filed 2016-11-14 | |||
| 2014-03-31 | $2.10M 10-Q · filed 2015-05-11 | $3.97M derived: sum of 2 quarters · filed 2016-11-14 | $5.93M derived: sum of 3 quarters · filed 2016-11-14 | $9.63M derived: sum of 4 quarters · filed 2016-11-14 | |||
| 2013-12-31 | $1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2016-11-14 | $3.83M derived: sum of 2 quarters · filed 2016-11-14 | $7.53M derived: sum of 3 quarters · filed 2016-11-14 | $8.83M 10-K · filed 2016-11-14 | |||
| 2013-09-30 | $1.97M 10-Q · filed 2014-10-31 | $5.66M derived: sum of 2 quarters · filed 2014-10-31 | $6.96M 10-Q · filed 2014-10-31 | ||||
| 2013-06-30 | $3.69M 10-Q · filed 2014-08-05 | $5.00M 10-Q · filed 2014-08-05 | |||||
| 2012-12-31 | -$2.67M 10-K · filed 2015-02-23 |